Heart Failure, Healthy Volunteer
Conditions
Keywords
Heart Failure, Cardiovascular Diseases, Heart Diseases, Ejection fraction, Heart Failure with reduced ejection fraction, Heart Failure with preserved ejection fraction
Brief summary
To evaluate the safety and tolerability of ascending single (Part A) and ascending multiple (Part B) doses of AMG 986 in healthy adults and of ascending multiple oral doses of AMG 986 in heart failure patients (Part C).
Detailed description
This study is a randomized, placebo-controlled, double-blind, single day ascending dose (SDAD) study (Part A), a multiple daily ascending dose (MDAD) study (Part B), in healthy adults, and a MDAD study (Part C) in heart failure patients. In Parts A and B of the study, healthy volunteers will receive AMG 986 by continuous IV infusion or by oral administration in a fasted state. IV Infusions will be divided into an initial loading dose (LD) for the first hour followed immediately by a maintenance dose (MD). In Part C of the study, patients with heart failure and either reduced (HFrEF) or preserved (HFpEF) ejection fraction will receive MDAD of AMG 986 or matching placebo once daily by oral administration for 21 days.
Interventions
DRUGAMG 986 IV
AMG 986 solution for infusion
DRUGAMG 986 PO
AMG 986 tablets for oral (PO) administration
DRUGPlacebo PO
Matching placebo tablets for oral administration
DRUGPlacebo IV
Matching placebo solution for infusion
Sponsors
Amgen
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Masking description
Double-blinded
Intervention model description
Double-blind, placebo-controlled
Eligibility
Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
Yes
Inclusion criteria
* Subject has provided informed consent prior to initiation of any study-specific activities/procedures. * Male and female subjects ≥ 18 to ≤ 55 years old with no history or evidence of clinically relevant medical disorders as determined by the investigator and the Amgen physician (Parts A and B only) * Body mass index (BMI) between 18 and 35 kg/m\^2, inclusive, at screening. * Physical examination including vital signs, clinical laboratory values, and electrocardiograms (ECGs) are clinically acceptable to the investigator. Abnormal findings for healthy volunteers and unexpected findings for heart failure patient subjects will be discussed with Amgen prior to study enrollment. * Women must be of non-reproductive potential (ie, postmenopausal) * Men must agree to practice an acceptable method of effective birth control while on study through 11 weeks after receiving the last dose of investigational product (AMG 986 or placebo). Acceptable methods of effective birth control include sexual abstinence; vasectomy and testing that shows there are no sperm in the semen; or a condom with spermicide (men) in combination with barrier methods (diaphragm, cervical cap or cervical sponge), hormonal birth control or IUS (women). * Men must be willing to abstain from sperm donation while on study through 11 weeks after receiving the last dose of investigational product (AMG 986 or placebo). * This inclusion criterion only applies to Parts B and C cohorts. Before inclusion in the study, subjects will undergo a screening echocardiogram to ensure that the following parameters can be accurately measured: left ventricular end-systolic and end-diastolic volumes, left atrial end-systolic and end-diastolic volumes, ejection fraction, fraction shortening, and end-systolic septal and posterior wall thickness. For Part C Additional Inclusion Criteria for HFrEF Patients: * Subject must be of age 18 to 85 years, have a diagnosis of HF confirmed by medical records for ≥ 3 months, and be in stable condition for at least 4 weeks. * Left ventricular ejection fraction (LVEF) ≤ 40% confirmed by echocardiogram, radionuclide ventriculography, cardiac magnetic resonance imaging, or contrast ventriculography within 12 months prior to randomization. * New York Heart Association (NYHA) class II or III at screening * Sinus rhythm * N-terminal pro b-type natriuretic peptide (NT-proBNP) level ≥ 250 pg/ml * Patients will be treated with stable, optimal pharmacological therapy for a minimum of 4 weeks prior to randomization. Treatment of HFrEF includes at least beta-blockers (carvedilol, metoprolol succinate or bisoprolol) and a RAAS inhibitor (ACEi, ARB or sacubitril/valsartan). Additional Inclusion Criteria for HFpEF patients: * Subject must be of age of 18 to 85 years, have a diagnosis of HF confirmed by medical records for ≥ 3 months, and be in stable condition for at least 4 weeks. * LVEF ≥ 50% confirmed by echocardiogram, radionuclide ventriculography, cardiac magnetic resonance imaging, or contrast ventriculography within 12 months prior to randomization. * LVEF never ≤ 40% in the past * NYHA class II or III at screening * Sinus rhythm * NT-proBNP level ≥ 250 pg/ml * Patients will be treated with stable, optimal pharmacological therapy for a minimum of 4 weeks prior to randomization. Treatment of HFpEF includes at least a daily dose of diuretics equivalent to furosemide 40 mg. * For subjects in Parts A, B and C: Women must have negative results for both the screening (serum) and day -1 (serum or urine) pregnancy tests
Exclusion criteria
* Currently receiving treatment in another investigational device or drug study, or less than 30 days or 5 half-lives (whichever is longer), since ending treatment on another investigational device or drug study(s) prior to receiving the first dose of investigational product (AMG 986 or placebo). * Female subjects who are lactating/breastfeeding or who plan to breastfeed while on study through 11 weeks after receiving the last dose of investigational product (AMG 986 or placebo). * Male subjects with partners who are pregnant or planning to become pregnant while the subject is on study through 11 weeks after receiving the last dose of investigational product (AMG 986 or placebo). * Female subjects of reproductive potential. * Subjects in Parts A and B of the study: estimated glomerular filtration rate (eGFR) within the screening period of less than 60 mL/min/1.73m\^2 as calculated using the estimated Modification of Diet in Renal Disease (MDRD) formula. * Current or prior malignancy within 5 years of randomization, with the exception of non-melanoma skin cancers, cervical or breast ductal carcinoma in situ, and adenocarcinoma of the prostate Stage I or IIa (defined as T1, T2a or T2b, N0, M0 with documented serum prostate-specific antigen (PSA) \< 20 ng/mL and Gleason score ≤ 7) per the American Joint Committee on Cancer (AJCC) primary tumor, regional lymph nodes, and distant metastasis system. * Positive results for human immunodeficiency virus (HIV), antibodies, hepatitis B surface antigen (HBsAg), or hepatitis C antibodies (HepCAb). * Subject has known sensitivity to any of the products or components to be administered during dosing. * Subject likely to not be available to complete all protocol required study visits or procedures, and/or to comply with all required study procedures to the best of the subject and investigator's knowledge. * History or evidence of any other clinically significant disorder, condition or disease with the exception of those outlined above that, in the opinion of the investigator or Amgen physician, if consulted, would pose a risk to subject safety or interfere with the study evaluation, procedures or completion. * Subject previously has entered this study or has been previously exposed to AMG 986. * Concurrent or prior use of strong CYP3A4 inhibitors within 14 days of study Day 1, including (not limited to): macrolide antibiotics (eg, clarithromycin, telithromycin), antifungals (eg, itraconazole, voriconazole), antivirals (eg, ritonavir, saquinavir, indinavir, nelfinavir), nefazodone. * Concurrent or prior ingestion of grapefruit or grapefruit products and other foods that are known to inhibit CYP3A4 within 7 days of study Day 1. * Concurrent or prior use of strong CYP3A4 inducers within 28 days of study Day 1, Including (not limited to): phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital. Subjects should also not take St John's Wort. * Concurrent or prior use of strong P-glycoprotein inhibitors within 28 days of study Day 1, including (not limited to): elacridar and valspodar. * All herbal supplements, vitamins, and nutritional supplements taken within the last 30 days prior to dosing on Day 1 (and continued use, if appropriate), must be reviewed and approved by the PI and Amgen Medical Monitor. * For subjects enrolled under Amendments 1-6, inclusive: QTc \> 450 msec or history/evidence of long QT syndrome. * Planned elective surgery within 30 days of study completion or before return of red blood cell parameters to normal values. * Blood donation ≥ 500 mL within 60 days of Day 1. * Systolic blood pressure \> 150 mmHg or \< 90 mmHg, or diastolic blood pressure \> 95 mmHg or \< 60 mmHg, assessed on 2 separate occasions prior to enrollment (Parts A and B only). * Heart rate ≥ 100 beats per minute after 5 minutes of rest or an untreated symptomatic bradyarrhythmia within 1 month prior to enrollment. * For Parts A and B: Troponin I at screening \> upper limit of normal (ULN). * In the opinion of the Investigator, a condition that compromises the ability of the subject to give written informed consent or to comply with study procedures. * Unwilling or unable to abstain from nicotine or tobacco containing products (including but not limited to: snuff, chewing tobacco, cigars, cigarettes, pipes, or nicotine patches) throughout the screening period and for the duration of the study. * Subjects who are unwilling or unable to limit alcohol consumption to 1 units/day (1 unit = 1 drink and 1 drink is equivalent to 12 ounces of regular beer, 8 to 9 ounces of malt liquor, 5 ounces of wine or 1.5 ounces of 80 proof distilled spirits). * Subjects with a positive urine drug screen or alcohol breath test. * Known history of drug or alcohol abuse. * Concurrent use of phosphodiesterase 5 (PDE5) inhibitors including (not limited to) avanafil, sildenafil, tadalafil, vardenafil. * Concurrent use of vasodilators by healthy subjects in Parts A and B that could in the opinion of the investigator potentially lead to a drop in blood pressure in combination with investigational product. * Severe uncorrected valvular heart disease, or hypertrophic obstructive cardiomyopathy, active myocarditis, constrictive pericarditis, or clinically significant congenital heart disease. * For subjects in Part C of the study: eGFR within the screening period of less than 30 mL/min/1.732m\^2 as calculated using the MDRD formula. * For subjects in Part C of the study: Systolic blood pressure \> 160 mmHg or \< 100 mmHg, or diastolic blood pressure \> 110 mmHg or \< 60 mmHg, assessed on 2 separate occasions prior to enrollment. * For subjects in Part C of the study: troponin I \> ULN if there is also evidence of an acute cardiovascular event. * For subjects enrolled in Part C under Amendment 7: QTc \> 500 msec or history/evidence of long QT syndrome.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Participants With Treatment Emergent Adverse Events (TEAE) | Part A: Day 1 up to Day 31 Part B: Day 1 up to Day 37 Part C: Day 1 up to Day 51 | An adverse event is defined as any untoward medical occurrence in a clinical trial subject. The event does not necessarily have a causal relationship with study treatment. Events categorized as TEAEs started on or after first dose of study drug and include up to 30 days after the last dose. A serious AE is an AE that met one or more of the following criteria: * Death * Life-threatening * Required inpatient hospitalization or prolongation of an existing hospitalization * Resulted in persistent or significant disability/incapacity * A congenital anomaly/birth defect * Important medical events that required medical or surgical intervention to prevent one of the outcomes above. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Left Ventricular Ejection Fraction by Visit for Part C Heart Failure With Reduced Ejection Fraction (HFrEF) Cohort | Baseline (Day 1 predose), Day 8, Day 15, Day 21, Day 30 | Heart failure (HF) refers to a clinical condition in which the cardiac output is insufficient to meet the metabolic needs of body organs and is marked by cardiac systolic and/or diastolic dysfunction. Heart failure with predominantly systolic dysfunction, which is identifiable as decreased contraction, is more aptly described as heart failure with reduced ejection fraction (HFrEF). Ejection fraction is a measurement, expressed as a percentage, of how much blood the left ventricle pumps out with each contraction and is measured by echocardiogram. |
| Stroke Volume (Method of Disks, Volumetric Assessment) by Visit for Part C Heart Failure With Reduced Ejection Fraction (HFrEF) Cohort | Baseline (Day 1 predose), Day 8, Day 15, Day 21, Day 30 | Stroke volume is the amount of blood pumped by the left ventricle of the heart in one contraction reported by volumetric method of disks (MoD) assessment. |
| Stroke Volume (Left Ventricular Outflow Tract Using Doppler Assessment) by Visit for Part C Heart Failure With Reduced Ejection Fraction (HFrEF) Cohort | Baseline (Day 1 predose), Day 8, Day 15, Day 21, Day 30 | Stroke volume is the amount of blood pumped by the left ventricle of the heart in one contraction as measured using left ventricular outflow tract (LVOT) Doppler assessment. |
Countries
Australia, Canada, France, Germany, Netherlands, New Zealand, Poland, Singapore, United States
Participant flow
Recruitment details
Participants were enrolled at 13 study centers in 7 countries (Canada, France, New Zealand, Netherland, Poland, Singapore, United States). The study included Parts A, B (healthy volunteers) and C (participants with either heart failure with reduced ejection fraction \[HFrEF\] or heart failure with preserved ejection fraction \[HFpEF\]). Each part of the study consisted of ascending dose cohorts.
Pre-assignment details
Within each dose cohort participants were randomized to AMG 986 or placebo in a 3:1 ratio. At the conclusion of each cohort, safety and tolerability of AMG 986 was reviewed before advancing to the next dose cohort. The Statistical Analysis Plan for this study specified that AMG 986 and Placebo-treated participants in Part A and Part B would be combined to form pooled AMG 986 and placebo groups, respectively for each Part.
Participants by arm
| Arm | Count |
|---|---|
| Part A: Placebo Pooled Healthy participants were administered placebo either intravenously (IV) or by mouth (PO) to match the 5 IV cohorts and 6 PO cohorts of AMG 986. | 22 |
| Part A: AMG 986 Pooled Healthy participants were administered a single dose of AMG 986 either IV or PO. The 5 IV cohorts started at a 0.5 mg loading dose over one hour up to the Cohort 5 IV dosage of a 60 mg loading dose over 1 hour and a 360 mg maintenance dose lasting 23 hours. The 6 PO cohorts started at a single 5 mg dose up to the Cohort 6 PO dose of 650 mg. | 66 |
| Part B: Placebo Pooled Healthy participants were administered placebo either IV for 4 consecutive days or PO for 7 days to match the 2 IV cohorts and 6 PO cohorts of AMG 986. | 16 |
| Part B: AMG 986 Pooled Healthy participants were administered AMG 986 either IV or PO. IV cohort 1 was administered a loading dose of 6 mg over one hour followed by maintenance doses of 36 mg lasting 23 hours on day 1 and 38 mg lasting 24 hours on days 2-4. IV cohort 2 was administered a loading dose of 60 mg lasting one hour followed by maintenance doses of 360 mg lasting 23 hours on day 1 and 376 mg lasting 24 hours on days 2-4. The 6 PO cohorts started at 5 mg for 7 days up to Cohort 6 PO dose of 650 mg for 7 days. | 50 |
| Part C: HFrEF Placebo Participants with heart failure with reduced ejection fraction (HFrEF) were administered a single PO placebo tablet daily from days 1-21. | 7 |
| Part C: HFpEF Placebo Participants with heart failure with preserved ejection fraction (HFpEF) were administered a single PO placebo tablet daily from days 1-21. | 1 |
| Part C: HFrEF AMG 986 Participants with heart failure with reduced ejection fraction (HFrEF) were administered a single PO AMG 986 tablet daily from days 1-21 in ascending doses of 10 mg for days 1-7, 30 mg for days 8-14 and 100 mg for days 15-21. | 17 |
| Part C: HFpEF AMG 986 Participants with heart failure with preserved ejection fraction (HFpEF) were administered a single PO AMG 986 tablet daily from days 1-21 in ascending doses of 10 mg for days 1-7, 30 mg for days 8-14 and 100 mg for days 15-21. | 3 |
| Total | 182 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 | FG004 | FG005 | FG006 | FG007 |
|---|---|---|---|---|---|---|---|---|---|
| Overall Study | Decision by sponsor | 0 | 0 | 0 | 0 | 1 | 0 | 2 | 1 |
| Overall Study | Lost to Follow-up | 0 | 0 | 2 | 2 | 0 | 0 | 0 | 0 |
| Overall Study | Withdrawal by Subject | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 0 |
Baseline characteristics
| Characteristic | Part A: AMG 986 Pooled | Part B: Placebo Pooled | Part B: AMG 986 Pooled | Part C: HFrEF Placebo | Part A: Placebo Pooled | Part C: HFpEF Placebo | Part C: HFrEF AMG 986 | Part C: HFpEF AMG 986 | Total |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | 39.5 years STANDARD_DEVIATION 9.8 | 36.9 years STANDARD_DEVIATION 10 | 37.4 years STANDARD_DEVIATION 9.8 | 61.6 years STANDARD_DEVIATION 10.1 | 37.2 years STANDARD_DEVIATION 9.4 | 73.0 years | 64.3 years STANDARD_DEVIATION 7.8 | 69.0 years STANDARD_DEVIATION 1 | 42.3 years STANDARD_DEVIATION 13.4 |
| Age, Customized 18-64 years | 66 Participants | 16 Participants | 50 Participants | 4 Participants | 22 Participants | 0 Participants | 11 Participants | 0 Participants | 169 Participants |
| Age, Customized 65-84 years | 0 Participants | 0 Participants | 0 Participants | 3 Participants | 0 Participants | 1 Participants | 6 Participants | 3 Participants | 13 Participants |
| Age, Customized 85 years and over | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Ethnicity (NIH/OMB) Hispanic or Latino | 22 Participants | 1 Participants | 5 Participants | 1 Participants | 6 Participants | 0 Participants | 0 Participants | 0 Participants | 35 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 44 Participants | 15 Participants | 45 Participants | 6 Participants | 16 Participants | 1 Participants | 17 Participants | 2 Participants | 146 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 1 Participants |
| Race/Ethnicity, Customized Asian | 6 Participants | 6 Participants | 11 Participants | 2 Participants | 3 Participants | 0 Participants | 2 Participants | 0 Participants | 30 Participants |
| Race/Ethnicity, Customized Black | 16 Participants | 5 Participants | 17 Participants | 2 Participants | 5 Participants | 0 Participants | 7 Participants | 2 Participants | 54 Participants |
| Race/Ethnicity, Customized Multiple | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 2 Participants | 0 Participants | 0 Participants | 0 Participants | 3 Participants |
| Race/Ethnicity, Customized Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants |
| Race/Ethnicity, Customized Other | 8 Participants | 0 Participants | 3 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 1 Participants | 13 Participants |
| Race/Ethnicity, Customized White | 35 Participants | 5 Participants | 18 Participants | 3 Participants | 11 Participants | 1 Participants | 8 Participants | 0 Participants | 81 Participants |
| Sex: Female, Male Female | 7 Participants | 0 Participants | 1 Participants | 3 Participants | 0 Participants | 1 Participants | 3 Participants | 2 Participants | 17 Participants |
| Sex: Female, Male Male | 59 Participants | 16 Participants | 49 Participants | 4 Participants | 22 Participants | 0 Participants | 14 Participants | 1 Participants | 165 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk | EG005 affected / at risk | EG006 affected / at risk | EG007 affected / at risk |
|---|---|---|---|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 22 | 0 / 66 | 0 / 16 | 0 / 50 | 0 / 7 | 0 / 1 | 0 / 17 | 0 / 3 |
| other Total, other adverse events | 3 / 22 | 8 / 66 | 2 / 16 | 7 / 50 | 2 / 7 | 1 / 1 | 6 / 16 | 3 / 3 |
| serious Total, serious adverse events | 0 / 22 | 0 / 66 | 0 / 16 | 0 / 50 | 0 / 7 | 0 / 1 | 0 / 16 | 1 / 3 |
Outcome results
Primary
Participants With Treatment Emergent Adverse Events (TEAE)
An adverse event is defined as any untoward medical occurrence in a clinical trial subject. The event does not necessarily have a causal relationship with study treatment. Events categorized as TEAEs started on or after first dose of study drug and include up to 30 days after the last dose. A serious AE is an AE that met one or more of the following criteria: * Death * Life-threatening * Required inpatient hospitalization or prolongation of an existing hospitalization * Resulted in persistent or significant disability/incapacity * A congenital anomaly/birth defect * Important medical events that required medical or surgical intervention to prevent one of the outcomes above.
Time frame: Part A: Day 1 up to Day 31 Part B: Day 1 up to Day 37 Part C: Day 1 up to Day 51
Population: All participants who received at least 1 dose of study drug
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Part A: Placebo Pooled | Participants With Treatment Emergent Adverse Events (TEAE) | All treatment-emergent adverse events (TEAEs) | 3 Participants |
| Part A: Placebo Pooled | Participants With Treatment Emergent Adverse Events (TEAE) | Serious adverse events | 0 Participants |
| Part A: Placebo Pooled | Participants With Treatment Emergent Adverse Events (TEAE) | Fatal adverse events | 0 Participants |
| Part A: Placebo Pooled | Participants With Treatment Emergent Adverse Events (TEAE) | TEAEs leading to discontinuation of study drug | 0 Participants |
| Part A: AMG 986 Pooled | Participants With Treatment Emergent Adverse Events (TEAE) | All treatment-emergent adverse events (TEAEs) | 11 Participants |
| Part A: AMG 986 Pooled | Participants With Treatment Emergent Adverse Events (TEAE) | Serious adverse events | 0 Participants |
| Part A: AMG 986 Pooled | Participants With Treatment Emergent Adverse Events (TEAE) | TEAEs leading to discontinuation of study drug | 0 Participants |
| Part A: AMG 986 Pooled | Participants With Treatment Emergent Adverse Events (TEAE) | Fatal adverse events | 0 Participants |
| Part B: Placebo Pooled | Participants With Treatment Emergent Adverse Events (TEAE) | Serious adverse events | 0 Participants |
| Part B: Placebo Pooled | Participants With Treatment Emergent Adverse Events (TEAE) | Fatal adverse events | 0 Participants |
| Part B: Placebo Pooled | Participants With Treatment Emergent Adverse Events (TEAE) | All treatment-emergent adverse events (TEAEs) | 2 Participants |
| Part B: Placebo Pooled | Participants With Treatment Emergent Adverse Events (TEAE) | TEAEs leading to discontinuation of study drug | 0 Participants |
| Part B: AMG 986 Pooled | Participants With Treatment Emergent Adverse Events (TEAE) | All treatment-emergent adverse events (TEAEs) | 7 Participants |
| Part B: AMG 986 Pooled | Participants With Treatment Emergent Adverse Events (TEAE) | Fatal adverse events | 0 Participants |
| Part B: AMG 986 Pooled | Participants With Treatment Emergent Adverse Events (TEAE) | Serious adverse events | 0 Participants |
| Part B: AMG 986 Pooled | Participants With Treatment Emergent Adverse Events (TEAE) | TEAEs leading to discontinuation of study drug | 0 Participants |
| Part C: HFrEF Placebo | Participants With Treatment Emergent Adverse Events (TEAE) | Fatal adverse events | 0 Participants |
| Part C: HFrEF Placebo | Participants With Treatment Emergent Adverse Events (TEAE) | Serious adverse events | 0 Participants |
| Part C: HFrEF Placebo | Participants With Treatment Emergent Adverse Events (TEAE) | All treatment-emergent adverse events (TEAEs) | 2 Participants |
| Part C: HFrEF Placebo | Participants With Treatment Emergent Adverse Events (TEAE) | TEAEs leading to discontinuation of study drug | 0 Participants |
| Part C: HFpEF Placebo | Participants With Treatment Emergent Adverse Events (TEAE) | TEAEs leading to discontinuation of study drug | 0 Participants |
| Part C: HFpEF Placebo | Participants With Treatment Emergent Adverse Events (TEAE) | Serious adverse events | 0 Participants |
| Part C: HFpEF Placebo | Participants With Treatment Emergent Adverse Events (TEAE) | All treatment-emergent adverse events (TEAEs) | 1 Participants |
| Part C: HFpEF Placebo | Participants With Treatment Emergent Adverse Events (TEAE) | Fatal adverse events | 0 Participants |
| Part C: HFrEF AMG 986 | Participants With Treatment Emergent Adverse Events (TEAE) | Serious adverse events | 0 Participants |
| Part C: HFrEF AMG 986 | Participants With Treatment Emergent Adverse Events (TEAE) | Fatal adverse events | 0 Participants |
| Part C: HFrEF AMG 986 | Participants With Treatment Emergent Adverse Events (TEAE) | All treatment-emergent adverse events (TEAEs) | 6 Participants |
| Part C: HFrEF AMG 986 | Participants With Treatment Emergent Adverse Events (TEAE) | TEAEs leading to discontinuation of study drug | 1 Participants |
| Part C: HFpEF AMG 986 | Participants With Treatment Emergent Adverse Events (TEAE) | TEAEs leading to discontinuation of study drug | 2 Participants |
| Part C: HFpEF AMG 986 | Participants With Treatment Emergent Adverse Events (TEAE) | Serious adverse events | 1 Participants |
| Part C: HFpEF AMG 986 | Participants With Treatment Emergent Adverse Events (TEAE) | All treatment-emergent adverse events (TEAEs) | 3 Participants |
| Part C: HFpEF AMG 986 | Participants With Treatment Emergent Adverse Events (TEAE) | Fatal adverse events | 0 Participants |
Secondary
Left Ventricular Ejection Fraction by Visit for Part C Heart Failure With Reduced Ejection Fraction (HFrEF) Cohort
Heart failure (HF) refers to a clinical condition in which the cardiac output is insufficient to meet the metabolic needs of body organs and is marked by cardiac systolic and/or diastolic dysfunction. Heart failure with predominantly systolic dysfunction, which is identifiable as decreased contraction, is more aptly described as heart failure with reduced ejection fraction (HFrEF). Ejection fraction is a measurement, expressed as a percentage, of how much blood the left ventricle pumps out with each contraction and is measured by echocardiogram.
Time frame: Baseline (Day 1 predose), Day 8, Day 15, Day 21, Day 30
Population: Participants who received study drug with available LVEF at each time point
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Part A: Placebo Pooled | Left Ventricular Ejection Fraction by Visit for Part C Heart Failure With Reduced Ejection Fraction (HFrEF) Cohort | Day 8 | 34.900 percent of total left ventricular blood | Standard Deviation 12.441 |
| Part A: Placebo Pooled | Left Ventricular Ejection Fraction by Visit for Part C Heart Failure With Reduced Ejection Fraction (HFrEF) Cohort | Day 21 | 33.550 percent of total left ventricular blood | Standard Deviation 8.896 |
| Part A: Placebo Pooled | Left Ventricular Ejection Fraction by Visit for Part C Heart Failure With Reduced Ejection Fraction (HFrEF) Cohort | Day 15 | 33.533 percent of total left ventricular blood | Standard Deviation 9.194 |
| Part A: Placebo Pooled | Left Ventricular Ejection Fraction by Visit for Part C Heart Failure With Reduced Ejection Fraction (HFrEF) Cohort | Day 30 | 33.171 percent of total left ventricular blood | Standard Deviation 8.14 |
| Part A: Placebo Pooled | Left Ventricular Ejection Fraction by Visit for Part C Heart Failure With Reduced Ejection Fraction (HFrEF) Cohort | Baseline | 33.300 percent of total left ventricular blood | Standard Deviation 8.42 |
| Part A: AMG 986 Pooled | Left Ventricular Ejection Fraction by Visit for Part C Heart Failure With Reduced Ejection Fraction (HFrEF) Cohort | Day 30 | 31.987 percent of total left ventricular blood | Standard Deviation 7.036 |
| Part A: AMG 986 Pooled | Left Ventricular Ejection Fraction by Visit for Part C Heart Failure With Reduced Ejection Fraction (HFrEF) Cohort | Baseline | 28.380 percent of total left ventricular blood | Standard Deviation 6.483 |
| Part A: AMG 986 Pooled | Left Ventricular Ejection Fraction by Visit for Part C Heart Failure With Reduced Ejection Fraction (HFrEF) Cohort | Day 8 | 32.553 percent of total left ventricular blood | Standard Deviation 7.055 |
| Part A: AMG 986 Pooled | Left Ventricular Ejection Fraction by Visit for Part C Heart Failure With Reduced Ejection Fraction (HFrEF) Cohort | Day 15 | 31.614 percent of total left ventricular blood | Standard Deviation 7.154 |
| Part A: AMG 986 Pooled | Left Ventricular Ejection Fraction by Visit for Part C Heart Failure With Reduced Ejection Fraction (HFrEF) Cohort | Day 21 | 31.436 percent of total left ventricular blood | Standard Deviation 5.953 |
Secondary
Stroke Volume (Left Ventricular Outflow Tract Using Doppler Assessment) by Visit for Part C Heart Failure With Reduced Ejection Fraction (HFrEF) Cohort
Stroke volume is the amount of blood pumped by the left ventricle of the heart in one contraction as measured using left ventricular outflow tract (LVOT) Doppler assessment.
Time frame: Baseline (Day 1 predose), Day 8, Day 15, Day 21, Day 30
Population: Participants who received study drug with available data at each time point
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Part A: Placebo Pooled | Stroke Volume (Left Ventricular Outflow Tract Using Doppler Assessment) by Visit for Part C Heart Failure With Reduced Ejection Fraction (HFrEF) Cohort | Day 8 | 52.657 mL | Standard Deviation 13.231 |
| Part A: Placebo Pooled | Stroke Volume (Left Ventricular Outflow Tract Using Doppler Assessment) by Visit for Part C Heart Failure With Reduced Ejection Fraction (HFrEF) Cohort | Day 21 | 55.805 mL | Standard Deviation 26.127 |
| Part A: Placebo Pooled | Stroke Volume (Left Ventricular Outflow Tract Using Doppler Assessment) by Visit for Part C Heart Failure With Reduced Ejection Fraction (HFrEF) Cohort | Day 15 | 53.985 mL | Standard Deviation 21.58 |
| Part A: Placebo Pooled | Stroke Volume (Left Ventricular Outflow Tract Using Doppler Assessment) by Visit for Part C Heart Failure With Reduced Ejection Fraction (HFrEF) Cohort | Day 30 | 55.113 mL | Standard Deviation 20.9 |
| Part A: Placebo Pooled | Stroke Volume (Left Ventricular Outflow Tract Using Doppler Assessment) by Visit for Part C Heart Failure With Reduced Ejection Fraction (HFrEF) Cohort | Baseline | 59.056 mL | Standard Deviation 18.12 |
| Part A: AMG 986 Pooled | Stroke Volume (Left Ventricular Outflow Tract Using Doppler Assessment) by Visit for Part C Heart Failure With Reduced Ejection Fraction (HFrEF) Cohort | Day 30 | 50.616 mL | Standard Deviation 14.212 |
| Part A: AMG 986 Pooled | Stroke Volume (Left Ventricular Outflow Tract Using Doppler Assessment) by Visit for Part C Heart Failure With Reduced Ejection Fraction (HFrEF) Cohort | Baseline | 54.739 mL | Standard Deviation 14.523 |
| Part A: AMG 986 Pooled | Stroke Volume (Left Ventricular Outflow Tract Using Doppler Assessment) by Visit for Part C Heart Failure With Reduced Ejection Fraction (HFrEF) Cohort | Day 8 | 53.512 mL | Standard Deviation 14.943 |
| Part A: AMG 986 Pooled | Stroke Volume (Left Ventricular Outflow Tract Using Doppler Assessment) by Visit for Part C Heart Failure With Reduced Ejection Fraction (HFrEF) Cohort | Day 15 | 53.073 mL | Standard Deviation 14.747 |
| Part A: AMG 986 Pooled | Stroke Volume (Left Ventricular Outflow Tract Using Doppler Assessment) by Visit for Part C Heart Failure With Reduced Ejection Fraction (HFrEF) Cohort | Day 21 | 53.858 mL | Standard Deviation 14.339 |
Secondary
Stroke Volume (Method of Disks, Volumetric Assessment) by Visit for Part C Heart Failure With Reduced Ejection Fraction (HFrEF) Cohort
Stroke volume is the amount of blood pumped by the left ventricle of the heart in one contraction reported by volumetric method of disks (MoD) assessment.
Time frame: Baseline (Day 1 predose), Day 8, Day 15, Day 21, Day 30
Population: Participants who received study drug with available data at each time point
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Part A: Placebo Pooled | Stroke Volume (Method of Disks, Volumetric Assessment) by Visit for Part C Heart Failure With Reduced Ejection Fraction (HFrEF) Cohort | Day 8 | 55.185 mL | Standard Deviation 19.158 |
| Part A: Placebo Pooled | Stroke Volume (Method of Disks, Volumetric Assessment) by Visit for Part C Heart Failure With Reduced Ejection Fraction (HFrEF) Cohort | Day 21 | 54.113 mL | Standard Deviation 18.789 |
| Part A: Placebo Pooled | Stroke Volume (Method of Disks, Volumetric Assessment) by Visit for Part C Heart Failure With Reduced Ejection Fraction (HFrEF) Cohort | Day 15 | 52.673 mL | Standard Deviation 19.514 |
| Part A: Placebo Pooled | Stroke Volume (Method of Disks, Volumetric Assessment) by Visit for Part C Heart Failure With Reduced Ejection Fraction (HFrEF) Cohort | Day 30 | 53.621 mL | Standard Deviation 19.258 |
| Part A: Placebo Pooled | Stroke Volume (Method of Disks, Volumetric Assessment) by Visit for Part C Heart Failure With Reduced Ejection Fraction (HFrEF) Cohort | Baseline | 53.387 mL | Standard Deviation 16.995 |
| Part A: AMG 986 Pooled | Stroke Volume (Method of Disks, Volumetric Assessment) by Visit for Part C Heart Failure With Reduced Ejection Fraction (HFrEF) Cohort | Day 30 | 44.634 mL | Standard Deviation 13.491 |
| Part A: AMG 986 Pooled | Stroke Volume (Method of Disks, Volumetric Assessment) by Visit for Part C Heart Failure With Reduced Ejection Fraction (HFrEF) Cohort | Baseline | 40.461 mL | Standard Deviation 14.193 |
| Part A: AMG 986 Pooled | Stroke Volume (Method of Disks, Volumetric Assessment) by Visit for Part C Heart Failure With Reduced Ejection Fraction (HFrEF) Cohort | Day 8 | 46.130 mL | Standard Deviation 13.927 |
| Part A: AMG 986 Pooled | Stroke Volume (Method of Disks, Volumetric Assessment) by Visit for Part C Heart Failure With Reduced Ejection Fraction (HFrEF) Cohort | Day 15 | 46.784 mL | Standard Deviation 14.348 |
| Part A: AMG 986 Pooled | Stroke Volume (Method of Disks, Volumetric Assessment) by Visit for Part C Heart Failure With Reduced Ejection Fraction (HFrEF) Cohort | Day 21 | 44.014 mL | Standard Deviation 12.051 |